Cogent Biosciences, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
Cogent Biosciences, Inc. (COGT) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of -1.30% for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-16.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2021-03-16
- Cogent Biosciences, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2020 was -1.30%.
- Cogent Biosciences, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2019 was -1.00%.
- Cogent Biosciences, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2018 was -0.70%, a 153.85% decline from fiscal 2017.
- Cogent Biosciences, Inc. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2017 was 1.30%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month as first filed |
|---|---|---|
| 2020-12-31 | -1.30% 10-K · filed 2021-03-16 | |
| 2019-12-31 | -1.00% 10-K · filed 2021-03-16 | |
| 2018-12-31 | -0.70% 10-K · filed 2020-03-26 | 0.70% 10-K · filed 2019-03-28 |
| 2017-12-31 | 1.30% 10-K · filed 2019-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |